Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1950 1
1951 3
1952 5
1953 1
1954 3
1955 2
1956 3
1957 8
1958 3
1959 3
1960 9
1961 2
1962 3
1963 2
1964 5
1965 6
1966 14
1967 23
1968 46
1969 42
1970 42
1971 68
1972 93
1973 119
1974 160
1975 175
1976 166
1977 171
1978 182
1979 269
1980 213
1981 235
1982 265
1983 311
1984 392
1985 445
1986 446
1987 458
1988 518
1989 610
1990 699
1991 887
1992 1038
1993 1216
1994 1446
1995 1705
1996 1836
1997 2035
1998 2284
1999 2408
2000 2591
2001 2685
2002 2864
2003 3159
2004 3478
2005 3570
2006 3889
2007 3953
2008 4089
2009 4456
2010 4764
2011 5114
2012 5753
2013 6037
2014 6632
2015 6920
2016 7200
2017 7551
2018 7736
2019 8202
2020 8864
2021 8737
2022 8506
2023 7932
2024 9585
2025 11700
2026 8091
2027 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

168,594 results

Results by year

Filters applied: . Clear all
Page 1
Estimating the Cost of Industry Investment in Drug Research and Development: A Review of Methods and Results.
Rennane S, Baker L, Mulcahy A. Rennane S, et al. Inquiry. 2021 Jan-Dec;58:469580211059731. doi: 10.1177/00469580211059731. Inquiry. 2021. PMID: 35170336 Free PMC article. Review.
Yet, there is little consensus on the actual cost of R&D for new drugs. We review and synthesize papers estimating drug R&D costs incurred by industry. We find a substantial range of per-drug costs, from $113 million to just over $6 bill …
Yet, there is little consensus on the actual cost of R&D for new drugs. We review and synthesize papers estimating drug R& …
Prescription drug cost sharing: associations with medication and medical utilization and spending and health.
Goldman DP, Joyce GF, Zheng Y. Goldman DP, et al. JAMA. 2007 Jul 4;298(1):61-9. doi: 10.1001/jama.298.1.61. JAMA. 2007. PMID: 17609491 Free PMC article. Review.
CONTEXT: Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug cost sharing could affect access to them. OBJECTIVE: To synthesize published evidence on the associations among cost-sharing featur …
CONTEXT: Prescription drugs are instrumental to managing and preventing chronic disease. Recent changes in US prescription drug co …
Drug cost avoidance in clinical trials of breast cancer.
Mañes-Sevilla M, Romero-Jiménez R, Herranz-Alonso A, Sánchez-Fresneda M, Gonzalez-Haba E, Collado-Borrel R, Benedi-González J, Sanjurjo-Sáez M. Mañes-Sevilla M, et al. J Oncol Pharm Pract. 2019 Jul;25(5):1099-1104. doi: 10.1177/1078155218775193. Epub 2018 May 23. J Oncol Pharm Pract. 2019. PMID: 29792122
BACKGROUND: The objectives of this study were to determine if clinical trials in breast cancer, with an investigational drug, created direct drug cost savings for the healthcare system related to cost avoidance of the best standard of care treatments u …
BACKGROUND: The objectives of this study were to determine if clinical trials in breast cancer, with an investigational drug, created …
Canadian drug cost reforms collapse.
Webster P. Webster P. Lancet. 2023 May 13;401(10388):1559. doi: 10.1016/S0140-6736(23)00956-X. Lancet. 2023. PMID: 37182523 No abstract available.
Characteristics of high-drug-cost beneficiaries of public drug plans in 9 Canadian provinces: a cross-sectional analysis.
Tadrous M, Martins D, Mamdani MM, Gomes T. Tadrous M, et al. CMAJ Open. 2020 Apr 28;8(2):E297-E303. doi: 10.9778/cmajo.20190231. Print 2020 Apr-Jun. CMAJ Open. 2020. PMID: 32345708 Free PMC article.
The objective of this study was to examine the characteristics of high-drug-cost beneficiaries of public drug plans across Canada relative to other beneficiaries. ...We stratified the cohort into 2 groups: high-drug-cost beneficiaries (top 5% of …
The objective of this study was to examine the characteristics of high-drug-cost beneficiaries of public drug plans acr …
Physician awareness of drug cost: a systematic review.
Allan GM, Lexchin J, Wiebe N. Allan GM, et al. PLoS Med. 2007 Sep;4(9):e283. doi: 10.1371/journal.pmed.0040283. PLoS Med. 2007. PMID: 17896856 Free PMC article.
BACKGROUND: Pharmaceutical costs are the fastest-growing health-care expense in most developed countries. Higher drug costs have been shown to negatively impact patient outcomes. ...Qualitative data related to physicians and drug costs were also …
BACKGROUND: Pharmaceutical costs are the fastest-growing health-care expense in most developed countries. Higher drug costs …
Bending Versus Transforming the Drug Cost Curve: A Matter of Political Will.
Major A, Polite BN. Major A, et al. Cancer J. 2020 Jul/Aug;26(4):304-310. doi: 10.1097/PPO.0000000000000458. Cancer J. 2020. PMID: 32732673 Free PMC article. Review.
There is increasing consensus that comprehensive reforms are needed to curb the rising costs of specialty drugs and growing bipartisan agreement on the basic principles that these reforms must address (1) constraints on yearly inflation of drug prices, (2) limits on …
There is increasing consensus that comprehensive reforms are needed to curb the rising costs of specialty drugs and growing bipartisa …
Clinical trials and drug cost savings for Italian health service.
D'Ambrosio F, De Feo G, Botti G, Capasso A, Pignata S, Maiolino P, Triassi M, Nardone A, Perrone F, Piezzo M, Grimaldi AM, Palazzo I, De Stasio I, D'Aniello R, Morabito A, Pascarella G. D'Ambrosio F, et al. BMC Health Serv Res. 2020 Nov 26;20(1):1089. doi: 10.1186/s12913-020-05928-6. BMC Health Serv Res. 2020. PMID: 33243262 Free PMC article.
BACKGROUND: The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost reduction for anticancer drug in the Italian Health Service due to patient participation in clinical trials. ...We used the market …
BACKGROUND: The cost of anticancer drugs is constantly growing. The aim of this study was determine the impact in terms of cost …
Difference in drug cost between private and public drug plans in Quebec, Canada.
M C, A F, I C, M S, L B. M C, et al. BMC Health Serv Res. 2022 Feb 14;22(1):200. doi: 10.1186/s12913-022-07611-4. BMC Health Serv Res. 2022. PMID: 35164750 Free PMC article.
This study compared the drug cost of Quebec residents covered by private drug plans with those covered by PDP. ...CONCLUSIONS: This study showed that, on average, drug cost is substantially higher for privately insured Quebecers. Knowing that ad …
This study compared the drug cost of Quebec residents covered by private drug plans with those covered by PDP. ...CONCL …
Comparison of claims from high-drug cost beneficiaries in Ontario, Canada, and Australia: a cross-sectional analysis.
Tadrous M, Daniels B, Pearson SA, Gomes T. Tadrous M, et al. CMAJ Open. 2021 Nov 23;9(4):E1048-E1054. doi: 10.9778/cmajo.20200291. Print 2021 Oct-Dec. CMAJ Open. 2021. PMID: 34815260 Free PMC article.
BACKGROUND: Globally, payers are struggling with rising drug costs, driven primarily by the increasing number of high-cost medications used by their beneficiaries. We aimed to compare the annual drug spending on claims from high-drug cost …
BACKGROUND: Globally, payers are struggling with rising drug costs, driven primarily by the increasing number of high-cost …
168,594 results
You have reached the last available page of results. Please see the User Guide for more information.